Journal
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
Volume 84, Issue -, Pages 272-288Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2017.08.019
Keywords
Major depressive disorder; Prefrontal cortex; Hippocampus; Amygdala; Nucleus accumbens; GWAS; Gene expression; RNA-sequencing; ChIP-sequencing; Epigenetics; Neural circuits
Categories
Funding
- Hope for Depression Research Foundation (HDRF)
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH104261, P50MH096890, R01MH051399] Funding Source: NIH RePORTER
Ask authors/readers for more resources
An estimated 50% of depressed patients are inadequately treated by available interventions. Even with an eventual recovery, many patients require a trial and error approach, as there are no reliable guidelines to match patients to optimal treatments and many patients develop treatment resistance over time. This situation derives from the heterogeneity of depression and the lack of biomarkers for stratification by distinct depression sub-types. There is thus a dire need for novel therapies. To address these known challenges, we propose a multi-scale framework for fundamental research on depression, aimed at identifying the brain circuits that are dysfunctional in several animal models of depression as well the changes in gene expression that are associated with these models. When combined with human genetic and imaging studies, our preclinical studies are starting to identify candidate circuits and molecules that are altered both in models of disease and in patient populations. Targeting these circuits and mechanisms can lead to novel generations of antidepressants tailored to specific patient populations with distinctive types of molecular and circuit dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available